# Boehringer Ingelheim Venture Fund

> Boehringer Ingelheim Venture Fund is a VC fund backing Biotechnology. See 104 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Ingelheim Am Rhein, Germany
- Total investments: 104
- Last investment: Jun 2026
- Lead investor: 47%
- Fund size: $250M
- Last fund: Jan 2018
- Last updated: Aug 2026
- Website: http://www.boehringer-ingelheim-venture.com

Boehringer Ingelheim Venture Fund is a VC fund in Ingelheim Am Rhein focused on Biotechnology and Health Care. Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

## Contacts

5 contacts available for Boehringer Ingelheim Venture Fund. Shizune tracks 4 team members at Boehringer Ingelheim Venture Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/boehringer-ingelheim-venture-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.8M–$20M |
| Series A | $3.8M–$34M |
| Series B | $11M–$50M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 45 | 43% |
| Health Care | 25 | 24% |
| Therapeutics | 24 | 23% |
| Medical | 18 | 17% |
| Life Science | 7 | 7% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 34 | 33% |
| Series B | 21 | 20% |
| Seed | 16 | 15% |
| Series C | 7 | 7% |
| Funding Round | 4 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 14 | 13% |
| Germany | 12 | 12% |
| Switzerland | 5 | 5% |
| Belgium | 4 | 4% |
| France | 3 | 3% |

14 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Debbie Lin | Executive Director | 1 | https://shizune.co/investors/profile/debbie-w-lin |
| Knut Elbers | Project Manager | 0 | https://shizune.co/investors/profile/knut-elbers |
| Martin Heidecker | Managing Director | 10 | https://shizune.co/investors/profile/martin-heidecker |
| Oliver Reuss | Executive Director and Investment Manager | 3 | https://shizune.co/investors/profile/oliver-reuss |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| smartbax | smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. |  | Seed | Jun 30, 2026 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M | Seed | Apr 29, 2026 |  |
| TECregen | TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. | $12.5M | Seed | Jan 08, 2026 |  |
| TECregen | TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. | $12.5M | Seed | Jan 08, 2026 |  |
| STRM.BIO | STRM.BIO specializes in the fields of biotechnology and life science. | $8M | Seed | Jan 07, 2026 |  |
| smartbax | smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. | $5.5M | Seed | Oct 22, 2025 |  |
| EvlaBio | EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). | $24.6M | Seed | Jul 07, 2025 |  |
| ArrePath | ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. |  | Seed | Jun 23, 2025 |  |
| Nuevocor | Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts. | $45M | Series B | May 06, 2025 |  |
| Brainomix | Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M | Series C | Mar 18, 2025 |  |

10 of 104 investments shown.

## Co-investors
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 17 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 11 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 9 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 8 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 8 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)

## FAQ

### What does Boehringer Ingelheim Venture Fund invest in?

Boehringer Ingelheim Venture Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 104 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Boehringer Ingelheim Venture Fund's check size?

Boehringer Ingelheim Venture Fund typically joins rounds of $1.8M–$20M at Seed, $3.8M–$34M at Series A and $11M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boehringer Ingelheim Venture Fund participates in.

### How do I contact Boehringer Ingelheim Venture Fund?

Public channels for Boehringer Ingelheim Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Boehringer Ingelheim Venture Fund?

The team at Boehringer Ingelheim Venture Fund includes Debbie Lin (Executive Director), Knut Elbers (Project Manager) and Martin Heidecker (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co